Rosetta Genomics Ltd.
ROSGQ · OTC
12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | 1.16 | 5.92 | 0.61 |
| FCF Yield | -10.05% | -7.72% | -4.54% | -3.34% |
| EV / EBITDA | -6.73 | -12.72 | -20.95 | -24.81 |
| Quality | ||||
| ROIC | -189.08% | -80.22% | -94.69% | -55.75% |
| Gross Margin | 19.44% | 24.14% | 1.28% | -75.06% |
| Cash Conversion Ratio | 0.64 | 0.98 | 0.94 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 90.91% | 173.31% | 87.60% | 57.84% |
| Free Cash Flow Growth | 38.45% | -24.24% | -23.28% | -26.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 0.75 | 0.56 | 1.30 |
| Interest Coverage | -364.28 | -327.52 | -365.44 | -889.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 38.23 | 177.80 | -38.32 | -133.86 |